Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types

Medientyp: E-Artikel

Titel: Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types

Beteiligte: Loeffler, Chiara Maria Lavinia; El Nahhas, Omar S. M.; Muti, Hannah Sophie; Carrero, Zunamys I.; Seibel, Tobias; van Treeck, Marko; Cifci, Didem; Gustav, Marco; Bretz, Kevin; Gaisa, Nadine T.; Lehmann, Kjong-Van; Leary, Alexandra; Selenica, Pier; Reis-Filho, Jorge S.; Ortiz-Bruechle, Nadina; Kather, Jakob Nikolas

Erschienen: Springer Science and Business Media LLC, 2024

Sprache: Englisch

DOI: 10.1186/s12915-024-02022-9

ISSN: 1741-7007

Entstehung:

Anmerkungen:

Beschreibung: Abstract Background Homologous recombination deficiency (HRD) is recognized as a pan-cancer predictive biomarker that potentially indicates who could benefit from treatment with PARP inhibitors (PARPi). Despite its clinical significance, HRD testing is highly complex. Here, we investigated in a proof-of-concept study whether Deep Learning (DL) can predict HRD status solely based on routine hematoxylin & eosin (H&E) histology images across nine different cancer types. Methods We developed a deep learning pipeline with attention-weighted multiple instance learning (attMIL) to predict HRD status from histology images. As part of our approach, we calculated a genomic scar HRD score by combining loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST) from whole genome sequencing (WGS) data of n = 5209 patients across two independent cohorts. The model’s effectiveness was evaluated using the area under the receiver operating characteristic curve (AUROC), focusing on its accuracy in predicting genomic HRD against a clinically recognized cutoff value. Results Our study demonstrated the predictability of genomic HRD status in endometrial, pancreatic, and lung cancers reaching cross-validated AUROCs of 0.79, 0.58, and 0.66, respectively. These predictions generalized well to an external cohort, with AUROCs of 0.93, 0.81, and 0.73. Moreover, a breast cancer-trained image-based HRD classifier yielded an AUROC of 0.78 in the internal validation cohort and was able to predict HRD in endometrial, prostate, and pancreatic cancer with AUROCs of 0.87, 0.84, and 0.67, indicating that a shared HRD-like phenotype occurs across these tumor entities. Conclusions This study establishes that HRD can be directly predicted from H&E slides using attMIL, demonstrating its applicability across nine different tumor types.

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: